Salidroside Inhibits the Proliferation of Gastric Cancer Cells by Regulating the miR-1343-3p/SOX18 Signaling Axis
Abstract
Objective
To investigate the molecular mechanism by which salidroside inhibits the proliferation of gastric cancer (GC) cells through upregulation of miR-1343-3p.
Methods
RNA databases were used to screen for mRNAs associated with tumor proliferation and with miR-1343-3p, and exhibiting significant changes in their expression levels after salidroside treatment of human GC cells. Gene matching and immunoprecipitation of RNA-binding proteins were conducted to analyze the association between miR-1343-3p and SOX18. Immunocytochemistry was performed to determine the localization of SOX18 protein. The effect of salidroside on the proliferation of human GC cells (MGC-803 and AGS) was determined by CCK-8 assay. Human GC cells were divided into a blank control group and low- and high-dose salidroside groups. The expression of miR-1343-3p and SOX18 mRNA was measured by real-time quantitative fluorescence PCR (qPCR). The protein expression of SOX18 was measured by Western blot. GC cells were co-transfected with miR-1343-3p mimic and miR-1343-3p inhibitor, respectively, via LipofectamineTM 2000 liposomes. The expression of miR-1343-3p and SOX18 mRNA was measured by qPCR, and the protein expression of SOX18 was measured by Western blot.
Results
Through bioinformatic analysis, SOX18 was identified as a downstream target of miR-1343-3p. Gene alignment confirmed the presence of specific binding sites between the two genes, and immunoprecipitation of RNA-binding proteins validated the targeting relationship between them (P < 0.05). Immunocytochemistry demonstrated the nuclear localization of SOX18 protein. CCK-8 assay findings demonstrated that salidroside significantly inhibited the proliferation of GC cells in a time- and dose-dependent manner. Compared with the blank control group, salidroside-treated GC cells showed decreased expression of both SOX18 mRNA and protein (P < 0.05) and an increased miR-1343-3p expression (P < 0.05). Compared with the control group, GC cells in the miR-1343-3p mimic group exhibited increased expression of miR-1343-3p and decreased expression of SOX18 mRNA and protein. In contrast, GC cells in the miR-1343-3p inhibitor group showed decreased expression of miR-1343-3p and increased expression of SOX18 mRNA and protein (all P < 0.05).
Conclusion
Salidroside may inhibit the proliferation of GC cells by regulating the miR-1343-3p/SOX18 signaling axis and these regulators may present new potential therapeutic targets or biomarkers for gastric cancer.
Keywords: Gastric cancer, Salidroside, miR-1343-3p, SOX18
Full Text:
PDFReferences
KALRA A, MELTZER S J. The role of DNA methylation in gastrointestinal disease: an expanded review of malignant and non-malignant gastrointestinal diseases. Gastroenterology, 2025, 168(2): 245-266. doi: 10.1053/j.gastro.2024.07.001.
ZHANG Z, YANG W, MA F, et al. Enhancing the chemotherapy effect of Apatinib on gastric cancer by co-treating with salidroside to reprogram the tumor hypoxia micro-environment and induce cell apoptosis. Drug Deliv, 2020, 27(1): 691-702. doi: 10.1080/10717544.2020.1754528.
FU Y, HUANG G, CAI Y, et al. Integrated network pharmacology, bioinformatics, and experiment analysis to decipher the molecular mechanism of Salidroside on Gastric cancer via targeting NCOA4-mediated ferritinophagy. Chem Biol Interact, 2025, 407: 111368. doi: 10. 1016/j.cbi.2024.111368.
ZHOU D, YANG D Q. miRNA is involved in the pathogenesis of multiple diseases by targeting osteoprotegerin. J Sichuan Univ (Med Sci), 2024, 55(3): 777-782. doi: 10.12182/20240560607.
WANG X, ZHANG Z, CAO X. Salidroside inhibited the proliferation of gastric cancer cells through up-regulating tumor suppressor miR-1343-3p and down-regulating MAP3K6/MMP24 signal molecules. Cancer Biol Ther, 2024, 25(1): 2322206. doi: 10.1080/15384047.2024.2322206.
ZHENG J J, QUE Q Y, XU H T, et al. Hypoxia activates SOX5/Wnt/β-Catenin signaling by suppressing MiR-338-3p in gastric cancer. Technol Cancer Res Treat, 2020, 19: 1533033820905825. doi: 10.1177/1533033820905825.
CHEN J Q, HUANG Z P, LI H F, et al. MicroRNA-520f-3p inhibits proliferation of gastric cancer cells via targeting SOX9 and thereby inactivating Wnt signaling. Sci Rep, 2020, 10(1): 6197. doi: 10.1038/s41598-020-63279-y.
XU W, LIANG T, FANG H, et al. Single-cell RNA sequencing identifies MMP11(+) cancer-associated fibroblasts as drivers of angiogenesis and bladder cancer progression. Adv Sci (Weinh), 2025: e02774. doi: 10.1002/advs. 202502774.
CHEN J, DANG Y, FENG W, et al. Correction: SOX18 promotes gastric cancer metastasis through transactivating MCAM and CCL7. Oncogene, 2021, 40(24): 4242-4243. doi: 10.1038/s41388-021-01828-z.
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263. doi: 10. 3322/caac.21834.
JONES L, CUNNINGHAM D, STARLING N. HER-2 directed therapies across gastrointestinal tract cancers - a new frontier. Cancer Treat Rev, 2024, 129: 102789. doi: 10.1016/j.ctrv.2024.102789.
SHAH M A, KENNEDY E B, ALARCON-ROZAS A E, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J Clin Oncol, 2023, 41(7): 1470-1491. doi: 10. 1200/JCO.22.02331.
XU W, DENG Z M, WANG X, et al. Network pharmacology study of compound ligustrazine in gastric cancer therapy. J Sichuan Univ (Med Sci), 2024, 55(5): 1114-1122. doi: 10.12182/20240960503.
LI J, YU D J, CHEN S H, et al. Relationship between the expression of human matricellular protein 3 and the pathological features, drug resistance, and prognosis of gastric cancer based on immunohistochemical method. J Sichuan Univ (Med Sci), 2024, 55(4): 893-901. doi: 10.12182/20240760205.
LIU F, LI M X, YAN J Y. Salidroside attenuates high phosphate-induced calcification of vascular smooth muscle cells via inhibiting TLR4/NF-κB pathway. J Sun Yat-Sen Univ (Med Sci), 2024, 45(6): 883-890. doi: 10. 13471/j.cnki.j.sun.yat-sen.univ(med.sci).20241021.002.
SĘCZYK Ł, SUGIER D, DERVIŞOĞLU G, et al. Phytochemical profile, in vitro bioaccessibility, and anticancer potential of golden root (Rhodiola rosea L. ) extracts. Food Chem, 2023, 404(Pt B): 134779. doi:10.1016/j. foodchem.2022.134779.
LIU S, LI Y, LI Z. Salidroside suppresses the activation of nasopharyngeal carcinoma cells via targeting miR-4262/GRP78 axis. Cell Cycle, 2022, 21(7): 720-729. doi: 10.1080/15384101.2021.2019976.
ZHANG X, ZHU J, YAN J, et al. Systems pharmacology unravels the synergic target space and therapeutic potential of Rhodiola rosea L. for non-small cell lung cancer. Phytomedicine, 2020, 79: 153326. doi: 10. 1016/j.phymed.2020.153326.
DING S Y, WANG M T, DAI D F, et al. Salidroside induces apoptosis and triggers endoplasmic reticulum stress in human hepatocellular carcinoma. Biochem Biophys Res Commun, 2020, 527(4): 1057-1063. doi: 10.1016/j. bbrc.2020.05.066.
ZHU X, LIU D, WANG Y, et al. Salidroside suppresses nonsmall cell lung cancer cells proliferation and migration via microRNA-103-3p/Mzb1. Anticancer Drugs, 2020, 31(7): 663-671. doi: 10.1097/CAD. 0000000000000926.
YANG R, MING Y J, WANG X J, et al. Salidroside suppresses proliferation and migration of non-small cell lung cancer cells via miRNA-210-3p/E2F3. Journal of Modern Oncology, 2023, 31(4): 625-631. doi: 10.3969/j.issn.1672-4992.2023.04.006.
REN M, XU W, XU T. Salidroside represses proliferation, migration and invasion of human lung cancer cells through AKT and MEK/ERK signal pathway. Artif Cells Nanomed Biotechnol, 2019, 47(1): 1014-1021. doi: 10.1080/21691401.2019.1584566.
MA L L, LI J H, WANG J S, et al. Expression of SOX18, VEGF-C and VEGFR-3 and their clinical significance in gastric carcinoma. Chinese Journal of Clinical and Experimental Pathology, 2013, 29(12): 1310-1312. doi: 10.13315/j.cnki.cjcep.2013.12.027.
Refbacks
- There are currently no refbacks.
